These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 9632278)

  • 1. Reduced progression-free survival in elderly patients receiving intensification with autologous peripheral blood stem cell reinfusion for multiple myeloma.
    Dumontet C; Ketterer N; Espinouse D; Neidhardt EM; Moullet I; Thieblemont C; Salles G; Coiffier B
    Bone Marrow Transplant; 1998 May; 21(10):1037-41. PubMed ID: 9632278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma.
    Huijgens PC; Dekker-Van Roessel HM; Jonkhoff AR; Admiraal GC; Zweegman S; Schuurhuis GJ; Ossenkoppele GJ
    Bone Marrow Transplant; 2001 May; 27(9):925-31. PubMed ID: 11436102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
    Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
    Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
    Alegre A; Granda A; Martínez-Chamorro C; Díaz-Mediavilla J; Martínez R; García-Laraña J; Lahuerta JJ; Sureda A; Bladé J; de la Rubia J; Fernández-Rañada JM; San Miguel J; ; ;
    Haematologica; 2002 Jun; 87(6):609-14. PubMed ID: 12031917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
    Brinker BT; Waller EK; Leong T; Heffner LT; Redei I; Langston AA; Lonial S
    Cancer; 2006 May; 106(10):2171-80. PubMed ID: 16598756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma.
    Qazilbash MH; Saliba RM; Hosing C; Mendoza F; Qureshi SR; Weber DM; Wang M; Flosser T; Couriel DR; De Lima M; Kebriaei P; Popat U; Alousi AM; Champlin RE; Giralt SA
    Bone Marrow Transplant; 2007 Mar; 39(5):279-83. PubMed ID: 17262062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission.
    Nadal E; Giné E; Bladé J; Esteve J; Rosiñol L; Fernández-Avilés F; Marin P; Martinez C; Rovira M; Urbano-Ispizua A; Carreras E; Montserrat E
    Bone Marrow Transplant; 2004 Jan; 33(1):61-4. PubMed ID: 14704657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose idarubicine, busulphan and melphalan as conditioning for autologous blood stem cell transplantation in multiple myeloma. A feasibility study.
    Meloni G; Capria S; Trasarti S; Ferrazza G; Micozzi A; Petrucci MT; Simone F; Trisolini SM; Mandelli F
    Bone Marrow Transplant; 2000 Nov; 26(10):1045-9. PubMed ID: 11108301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.
    Martino M; Console G; Irrera G; Praticò G; Stelitano C; Callea V; Morabito F; Quartarone E; Musolino C; Piro E; Brugiatelli M; Iacopino P
    Am J Hematol; 2006 Dec; 81(12):973-8. PubMed ID: 16888786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis.
    Kumar SK; Dingli D; Lacy MQ; Dispenzieri A; Hayman SR; Buadi FK; Rajkumar SV; Litzow MR; Gertz MA
    Am J Hematol; 2008 Aug; 83(8):614-7. PubMed ID: 18429054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melphalan and dexamethasone for patients with multiple myeloma who are not candidates for autologous stem cell transplantation.
    Sharma A; Lokeshwar N; Raina V; Mohanti BK; Kumar R
    Natl Med J India; 2007; 20(3):121-4. PubMed ID: 17867615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
    Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ;
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
    Kröger N; Perez-Simon JA; Myint H; Klingemann H; Shimoni A; Nagler A; Martino R; Alegre A; Tomas JF; Schwerdtfeger R; Kiehl M; Fauser A; Sayer HG; Leon A; Beyer J; Zabelina T; Ayuk F; San Miguel JF; Brand R; Zander AR
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):698-708. PubMed ID: 15389436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensification of the stem cell transplant induction regimen results in increased treatment-related mortality without improved outcome in multiple myeloma.
    Abraham R; Chen C; Tsang R; Simpson D; Murray C; Davidson M; Meharchand J; Sutton DM; Crump RM; Keating A; Stewart AK
    Bone Marrow Transplant; 1999 Dec; 24(12):1291-7. PubMed ID: 10627637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
    Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
    Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
    Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
    Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous stem cell transplantation for relapsed and primary refractory myeloma.
    Rajkumar SV; Fonseca R; Lacy MQ; Witzig TE; Lust JA; Greipp PR; Therneau TM; Kyle RA; Litzow MR; Gertz MA
    Bone Marrow Transplant; 1999 Jun; 23(12):1267-72. PubMed ID: 10414914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.